Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Cash: 2014-2024

Historic Change in Cash for Theravance Biopharma (TBPH) over the last 11 years, with Dec 2024 value amounting to -$1.7 million.

  • Theravance Biopharma's Change in Cash fell 366.56% to -$107.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.4 million, marking a year-over-year increase of 413.40%. This contributed to the annual value of -$1.7 million for FY2024, which is 99.32% up from last year.
  • Theravance Biopharma's Change in Cash amounted to -$1.7 million in FY2024, which was up 99.32% from -$258.6 million recorded in FY2023.
  • In the past 5 years, Theravance Biopharma's Change in Cash registered a high of $208.2 million during FY2022, and its lowest value of -$258.6 million during FY2023.
  • Its 3-year average for Change in Cash is -$17.4 million, with a median of -$1.7 million in 2024.
  • Per our database at Business Quant, Theravance Biopharma's Change in Cash spiked by 2,350.71% in 2022 and then tumbled by 224.21% in 2023.
  • Theravance Biopharma's Change in Cash (Yearly) stood at $23.4 million in 2020, then tumbled by 63.70% to $8.5 million in 2021, then surged by 2,350.71% to $208.2 million in 2022, then slumped by 224.21% to -$258.6 million in 2023, then soared by 99.32% to -$1.7 million in 2024.